الفهرس 
Hepatitis C virus (HCV) & Direct actingOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
Abstract
Aim of the work: the current study examined effect of diabetic control on achieving sustained virologic response (SVR) in chronic hepatitis C virus (HCV) patients who received Direct-Acting Antivirals (DAAs) (Daclatasvir (DCV)+ Sofosbuvir (SOF)± Ribavirin (RBV) for 12 weeks) according to the recommendations of The Egyptian National Committee for Control of Viral Hepatitis (December 2016). Patients and methods: this study was conducted in the Gastroenterology and Hepatology Unit, Internal Medicine Department, Ain Shams University Hospital. It was included 100 patients with chronic HCV infection (Treatment naive patients) (Child’s A patients). All patients were subjected to history taking, through clinical examination, laboratory investigations, abdominal ultrasonography and calculation of FIB-4 score. Patients were classified in to 3 groups according to diabetic control. PCR for HCV RNA was assessed at 12 weeks post-treatment to evaluate SVR. Results: our results revealed that diabetic control seemed not to reduce SVR to DAAs (DCV + SOF ± RRV for 12 weeks) in chronic HCV infected patients. Overall, SVR was achieved by 91% of the 100 patients including 91.8% of patients treated with SOF+DAC and 89.7% of those treated with SOF+DAC+RBV.
Conclusion: our results showed that DCV + SOF ± RBV combination for 12 weeks is an effective and well tolerated regimen for patients with chronic HCV (treatment naive patients) (Child’s A patients). Overall SVR of 91%.has been achieved. Also, diabetic control seems not to affect SVR sates in these patients. Although the management of metabolic alterations remains a relevant strategy to limit liver disease progression, the optimization of virologic response to DAAs based regimens should focus on factors other than diabetic control.